ALN-SOD + Placebo (PB)
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis (ALS)
Conditions
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Trial Timeline
Aug 28, 2024 → Jun 5, 2031
NCT ID
NCT06351592About ALN-SOD + Placebo (PB)
ALN-SOD + Placebo (PB) is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Amyotrophic Lateral Sclerosis (ALS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06351592. Target conditions include Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06351592 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis (ALS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 44 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 52 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 23 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 65 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 65 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 77 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 52 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 33 |
| TCH346 | Novartis | Phase 2 | 52 |
| VHB937 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| BLZ945 | Novartis | Phase 2 | 52 |
| TRO19622 | Roche | Phase 2/3 | 65 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 77 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 51 |